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Background: Breast cancer often metastasizes into bone and leads to osteolytic lesions. The underlying
mechanisms, however, are complex and not fully understood. Syndecan-1 is a proteoglycan that has
various functions relevant for tumor progression including cell–cell communication and cell–matrix
interactions. Moreover, its two glycosaminoglycan-binding sites suggest that it may interfere with
glycoproteins such as osteoprotegerin, a potent inhibitor of osteoclastogenesis. Thus, we hypothesize that
tumor-derived syndecan-1 alters osteoclast biology by modulating osteoprotegerin.
Methods: Syndecan-1 expression was down-regulated via siRNA and the cell fate of the breast cancer cell
lines MCF-7, T-47D, and MDA-MB-231 was investigated. Furthermore, we determined the regulation of
syndecan-1 by dexamethasone, a commonly used antiemetic in breast cancer therapy. Additionally, we
analyzed the genesis and activity of osteoclasts in indirect co-culture experiments using supernatants
from MCF-7 cells with deﬁcient and sufﬁcient levels of syndecan-1.
Results: Dexamethasone time- and dose-dependently increased syndecan-1 expression up to 4-fold but
did not alter cell behavior. Syndecan-1 up-regulation did not affect the survival or migration of breast
cancer cells. Depletion of syndecan-1 using siRNA led to decreased vitality of progesterone receptor-
positive cell lines. In MCF-7 cells osteoprotegerin production was up-regulated 2.5-fold after syndecan-1
knock-down. The culture of osteoclast precursors with the supernatant of MCF-7 cells with reduced
syndecan-1 levels suppressed osteoclast formation and activity by 21% and 23%, respectively. Adding
neutralizing antibodies to osteoprotegerin to the breast cancer supernatants reversed osteoclastogenesis.
Conclusion: Thus, we identiﬁed tumor-derived syndecan-1 as a novel positive regulator of osteoclasto-
genesis and new player in the tumor-bone dialog.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The proteoglycan syndecan-1 (also known as CD138) interacts
with a variety of proteins via its heparin sulfate side chains or the
core protein itself and therefore regulates key cellular functions
such as apoptosis, proliferation, and epithelial-mesenchymal
transition [1–7]. Because of its various interactions, several studies
have investigated the role of syndecan-1 in tumor progression.
While in multiple myeloma, high serum levels of soluble
syndecan-1 correlate with a poor prognosis, the association of
syndecan-1 expression and clinical outcome was ambiguous in
breast cancer [8–11]. One study found a correlation between
stromal and epithelial syndecan-1 expression and poor prognosis,
whereas another study observed a poor clinical outcome in breast
cancer cases without syndecan-1 expression [9,10]. Although
the exact reasons for these different ﬁndings remain unclear, it
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has been suggested that they may related to the presence of two
functionally different syndecan-1 isoforms [5]. While membra-
nous syndecan-1 facilitates the proliferation of breast cancer cells,
the soluble form triggers invasion [5]. Despite extensive efforts to
unravel the role of syndecan-1 in breast cancer, little is known
about how it is regulated. Of note, zoledronic acid, a widely used
drug against osteoporosis and skeletal metastases, was found to
inhibit syndecan-1 expression in breast cancer cell lines [12].
In multiple myeloma, the interaction between syndecan-1 and
osteoprotegerin (OPG), the physiological antagonist of the osteoclast
promoting factor receptor activator of NF-κB (RANKL), has been
investigated in more detail [13]. The observed syndecan-1-mediated
internalization and degradation of OPG may explain low OPG serum
levels in patients with multiple myeloma [13]. Furthermore, two
other studies demonstrated that tumor-derived syndecan-1 affects
bone physiology [14,15].
Here, we aimed to identify novel regulators of syndecan-1 in
breast cancer. We hypothesized that changes in syndecan-1
expression affect osteoclastogenesis. Our results show that
(i) dexamethasone increases syndecan-1 expression and that
(ii) depletion of syndecan-1 decreases cell viability of hormone
receptor-positive breast cancer cells and increases OPG expression,
thus suppressing osteoclast differentiation and activation. Hence,
syndecan-1 participates in the tumor-bone dialog and alters the
bone microenvironment to stimulate osteoclastogenesis.
2. Methods
2.1. Cultivation and treatment of cells
All breast cancer cell lines (MCF-7, T-47D, and MDA-MB-231)
were cultured in DMEM/Ham's F-12 (PAA, Pasching, Austria), 10%
fetal calf serum (FCS) supreme (Lonza, Pasching, Austria) and 1%
penicillin/streptomycin (PAA, Pasching, Austria). Cells were grown
in a humidiﬁed atmosphere of 95% air and 5% CO2. To assess the
effects of dexamethasone (DEX), 70% conﬂuent cells were serum
starved for 12 h prior to DEX exposure (Sigma-Aldrich, Darmstadt,
Germany) in various concentrations (109–106 M). To antagonize
the effects of DEX, RU-486 (Calbiochem, Darmstadt, Germany) was
used at a concentration of 105 M. Cells were also treated with
zoledronic acid (ZOL, provided by Novartis, Nürnberg, Germany)
and the aromatase inhibitor (AI) 4-(imidazolyl)-1nitro-9H-9-
xanthenone (Calbiochem, Darmstadt, Germany) in various con-
centrations (ZOL: 1010–106 M, AI: 7.5108 M and 107 M).
To obtain osteoclasts, peripheral blood mononuclear cells
(PBMCs) were isolated using Biocoll (1.077 g/ml, Biochrom, Berlin,
Germany) from buffy coats obtained after informed consent and
following IRB approval and plated at a density of 2106 cells/cm2
in α-MEM (Invitrogen, Darmstadt, Germany) containing 10% FCS
and 1% penicillin/streptomycin. After attachment cells were cul-
tured with 25 ng/ml M-CSF and 50 ng/ml RANKL for 21 d. For
indirect cell culture, osteoclasts were cultured in 1/3 osteoclast
culture media (α-MEM containing M-CSF and RANKL)þ2/3 super-
natant of MCF-7 cells from control cells and cells where syndecan-
1 expression had been inhibited using siRNA.
2.2. Knock-down experiments
For knock-down experiments, SDC1 siRNA (ID 12527, Ambion,
Applied Biosystems, Darmstadt, Germany) and for scrambled control
Silencers Select Negative Control #1 (Cat#4390844 Ambion, Applied
Biosystems, Darmstadt, Germany) was introduced in cells with
DharmaFECT 1 (Thermo Fisher Scientiﬁc, Schwerte, Germany). Dhar-
maFECT1 reagent and siRNA were separately incubated in FCS-free
medium (OPTI-MEMs IþGlutaMAX™—I, Invitrogen Karlsruhe,
Germany) for 5 min and subsequently mixed and incubated for
20 min at room temperature. Thereafter, medium containing 10%
FCS without penicillin/streptomycin was added to the siRNA and
DharmaFECT-mixture to the ﬁnal concentration of 50 nM. Breast
cancer cells were washed with PBS and incubated with the transfec-
tion mixture for 5 h. Mediumwas change to stop the transfection and
the cells were treated as described above.
2.3. RNA isolation and real-time PCR
RNA was isolated using HighPure RNA extraction kit (Roche,
Mannheim, Germany) according to the manufacturer's protocol. Five
hundred ng RNA were reverse transcribed using SuperScript II
(Invitrogen, Darmstadt, Germany) and subsequently used for SYBR
green-based real-time PCR using a standard protocol (Roche, Man-
nheim, Germany). Primers (Sigma-Aldrich, Munich, Germany) used
for semi-quantitative analyses of gene expression: ACTB (β-actin)
[NCBI GenBank:NM_001101]: CCAACCGCGAGAAGATGA, CCAGAGGCG-
TACAGGGATAG, GAPDH (glyceraldehyde 3-phosphate-dehydrogenase)
[NCBI GenBank:NM_002046]: AGCCACATCGCTCAGACAC, GCCCAATA-
CGACCAAATCC, SDC1 (syndecan-1) [NCBI GenBank:NM_001006946]:
TGGACAGGAAAGAGGTGCTG, GTTTGGTGGGCTTCTGGTAG, OPG (osteo-
protegerin) [NCBI GenBank:NM_002546]: GAACCCCAGAGCGAAATA-
CAG, TAGCAGGAGACCAAAGACACTG, RANK (receptor activator of
NF-κB) [NCBI GenBank:NM_001270949]: ATCTGGGACGGTGCTGTAAC,
CACAGGGCAGACATACACTG, RANKL (receptor activator of NF-κB
ligand) [NCBI GenBank:NM_003701]: CTGATGAAAGGAGGAAGCAC,
AGTAAGGAGGGGTTGGAGAC.
PCR conditions were 95 1C for 10 min followed by 40 cycles
with 95 1C for 10 s, 56 1C for 10 s and 72 1C for 30 s. The melting
curve was assessed with the following program: 60 1C for 1 min
and 95 1C continuously. The results were calculated applying
the ΔΔCT method, and are presented in x-fold increase relative
to ACTB.
2.4. Tissue qPCR array
The Tissue Scan Breast Cancer Tissue qPCR Panel II (OriGene
Technologies, Inc., Rockville, USA, Cat. no. BCRT 301) was performed
according to the manufacturer's protocol. For this study syndecan-1
was analyzed and normalized to ACTB (see Section 2.3).
2.5. Protein analyses
For the detection of membrane-bound proteins, the cells were
cultured on cover slips and treated as described above. Subse-
quently cells were washed with PBS and ﬁxed with ice-cold
methanol for 1 h and 20 1C. Afterwards cells were rehydrated
with PBS for 10 min and 37 1C. To avoid nonspeciﬁc binding, cells
were incubated in 1% BSA for 1 h prior incubation with speciﬁc
primary antibodies over night at 4 1C. Cells were than washed with
PBS and treated with secondary ﬂuorescence antibody for 1 h,
washed twice and nuclei were stained with DAPI (2.5 mg/ml). Cells
were washed three times with PBS and mounted with Dako
Fluorescence Mounting Medium (Dako, Dako Deutschland GmbH,
Hamburg, Germany).
The following primary and secondary antibodies for immuno-
ﬂuorescence staining were used for detection of syndecan-1:
AM00592SU-N (Acris), OPG (osteoprotegerin) AF 805, (R&D), goat
anti-mouse Alexa Fluor 488 (green, for SDC1) and rabbit anti-goat
Alexa Fluor 594 (red, for OPG). For ﬂuorescence microscopy the
Axio M1 microscope (Carl Zeiss, Jena, Germany) was used.
For soluble proteins ELISAs for syndecan-1 (Diaclone, Besancon,
France) and OPG (Immundiagnostik, Bensheim, Germany), were
used according to the manufacturer's protocol.
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2.6. Functional analyses of breast cancer cells
Cell viability was assessed using the CellTiterBlues Assay
(Promega, Mannheim, Germany) and apoptosis using the Cell
Death Detection ELISA PLUS (Roche, Mannheim, Germany) accord-
ing to the manufacturer's protocol. Measurements were conducted
using the FluoStar Omega (BMG Labtech, Jena, Germany).
A scratch assay was used to investigate the migration of MCF-7
cells. The cells were cultured and a scratch was done with a tip
through the monolayer when they reached conﬂuence. At time
point 0 and 72 h, pictures of the scratch were taken. For analyses
the scratch size was measured at 10 different regions with Image j
software.
2.7. Analyses of osteoclastogenesis and activity of osteoclasts
To analyze osteoclastogenesis, cells from the indirect co-culture
were ﬁxed with an acetone/citrate buffer and afterwards stained
for tartrate-resistant acid phosphatase (TRAP kit, Sigma, Munich,
Germany). TRAP-positive cells with three or more nuclei were
counted as osteoclasts. For measurement of osteoclast activity the
OsteoLyse assay (Lonza, Pasching, Austria) was used according to
the manufacturer's protocol. Brieﬂy, osteoclast precursors were
plated onto the OsteoLyse™ cell culture plate and cultured in
medium that contained 33 ng/ml M-CSF and 66 ng/ml RANKL.
After 7 days, medium was changed to medium consisting of 1/3 of
osteoclast culture medium and 2/3 supernatant from syndecan-1
sufﬁcient and insufﬁcient MCF-7 cells.
2.8. Statistical analysis
Results are presented as means7standard deviation. All experi-
ments were repeated at least three times. Outliers were determined
via Grubb's test. Statistical evaluations for time- and dose-response
curves were performed using a one-way analysis of variance
(ANOVA) with posthoc Dunns test and single group comparisons
using Student's t-test. P-valueso0.05 were considered statistically
signiﬁcant.
3. Results
3.1. Syndecan-1 expression in breast cancer cell lines and primary
breast cancer tissue
The two hormone receptor-positive cell lines MCF-7, T-47D, and
the hormone receptor-negative MDA-MB-231 cells were used
to comprehensively investigate the role of syndecan-1 in breast
cancer cells. First, we analyzed the syndecan-1 expression in all
three cell lines using real-time PCR (Fig. 1A) and immunoﬂuores-
cence staining for membranous syndecan-1 (Fig. 1B). All cell lines
expressed syndecan-1 with the highest levels in MCF-7 cells.
Fig. 1. Syndecan-1 (SDC1) expression in breast cancer. SDC1 expressionwas analyzed using (A) real-time PCR and (B) immunoﬂuorescence staining. Therefore, the cells were
cultured in medium with 10% FCS and 1% penicillin/streptomycin. Syndecan-1 is displayed in green, the nucleus in blue. Correlation of SDC1 expression with (C) tumor stage
and important (D) tumor markers were analyzed. N¼3, magniﬁcation 400 , ERBB2—v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, ER—estrogen receptor,
MDA—MDA-MB-231, PR—progesterone receptor, and SDC1—syndecan-1.
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While syndecan-1 was mainly located at the cell surface in MCF-7
cells, T-47D and MDA-MB-231 cells showed a lower and diffuse
cytoplasmic signal for syndecan-1.
In addition, we performed a Tissue Scan Breast Cancer Tissue
qPCR Array to assess whether syndecan-1 expression is correlated
with important tumor characteristics (ER, PR, ERBB2 expression or
tumor stage). Syndecan-1 expression was observed in healthy and
cancer tissue but no signiﬁcant differences were found between
these groups or within different tumor stages (Fig. 1C). Analyses of
syndecan-1 with other parameters such as hormone receptor status
and ERBB2 expression did not show signiﬁcant correlations (Fig. 1D).
3.2. Dexamethasone enhanced syndecan-1 expression in MCF-7 cells
Next, we investigated syndecan-1 regulation in breast cancer cells
after treatment with zoledronic acid (1010–106 M); aromatase
inhibitor 4-(imidazolyl)-1nitro-9H-9-xanthenone, (7.5108 M and
107 M) and dexamethasone (109–106). Here, the most promi-
nent effect was observed in MCF-7 cells after dexamethasone
treatment (Fig. 2). Syndecan-1 mRNA levels were dose- (Fig. 2A)
and time-dependently (Fig. 2B) induced by dexamethasone with
the highest effect after 72 h and a concentration of 106 M. The
dexamethasone-dependent induction of syndecan-1 was inhibited
by the glucocorticoid-receptor antagonist RU-486 (Fig. 2C), which
can also bind to the progesterone receptor [16]. For syndecan-1
protein analyses, we used immunoﬂuorescence staining to detect the
membrane-bound form (Fig. 2D) and ELISA (Fig. 2E) to detect the
soluble form. We found that dexamethasone-treated MCF-7 cells
showed a more intense immunoﬂuorescence signal for syndecan-1
at the cell surface compared to control and RU-486-treated cells
(Fig. 2D). No effect of dexamethasone was observed on the soluble
syndecan-1 expression (Fig. 2E).
In contrast to MCF-7 cells, dexamethasone did not alter the
syndecan-1 expression of T-47D (Fig. S1) and MDA-MB-231 (Fig S2)
cells. Furthermore, neither zoledronic acid nor aromatase-inhibitor
affected syndecan-1 expression of MCF-7 and MDA-MB-231 cells
(data not shown).
3.3. Functional relevance of syndecan-1 modulation
As syndecan-1 is involved in a variety of cell functions, we
studied the role of dexamethasone-induced syndecan-1 expression
in MCF-7. The viability of MCF-7 cells was slightly reduced (11%)
after dexamethasone treatment (Fig. 3A) but no differences were
observed for apoptosis (Fig. 3B) and cell migration (Fig. 3C).
To assess the role of syndecan-1 in breast cancer cell biology
more directly, syndecan-1 expression was inhibited in all three cell
lines using siRNA (Fig. S3). We found that the viability of hormone
receptor-positive breast cancer cells MCF-7 and T-47D was
reduced by 20% (po0.001) and 13% (po0.001), respectively, after
inhibition of syndecan-1 expression (Fig. 3D). The viability of the
hormone receptor-negative MDA-MB-231 cell line was not altered
after syndecan-1 knock-down (Fig. 3D).
3.4. Osteoprotegerin is up-regulated after syndecan-1 knock-down
in MCF-7 cells
Because of the known interaction of syndecan-1 with OPG we
analyzed the expression of OPG, RANK and RANKL after syndecan-
1 knock-down in MCF-7 cells. The mRNA expression as well as the
Fig. 2. Dexamethasone enhances syndecan-1 (SDC1) expression in MCF-7 cells. For analyzing DEX-effects MCF-7 cells were serum starved 12 h prior to and during
treatment. MCF-7 cells were treated with (A) different doses of dexamethasone (DEX) for 72 h or with (B) 106 M DEX for 24, 48, and 72 h. Afterwards the SDC1 expression
was analyzed using real-time PCR. (C) The receptor antagonist RU-486 (105 M) was used to inhibit the DEX effects in MCF-7 cells. To analyze the protein expression of SDC1
in more detail we used (D) immunoﬂuorescence staining for the membrane bound form and (E) ELISA for the soluble form. SDC1 is displayed in green, the nucleus in blue.
N¼3, npo0.05, nnnpo0.001, magniﬁcation 400 , DEX—dexamethasone, RU—RU-486, and SDC1—syndecan-1.
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protein secretion of OPG was up-regulated 2.5-fold (Fig. 4A) and
1.8 fold (Fig. 4B), respectively. For T-47D (Fig. S4A) and MDA-MB-
231 (Fig. S4B) cells, OPG expression after syndecan-1 knock-down
was also analyzed. Compared with the OPG regulation in MCF-7
cells only minimal up-regulation of OPG was observed for MDA-
231 (Fig. S4B) and no altered OPG expression for T-47D (Fig. S4A).
Syndecan-1 knock-down did not alter the mRNA expression of
RANK and RANKL in all three cell lines (data not shown).
3.5. Osteoclastogenesis is inhibited by the supernatant from MCF-7
cells with reduced syndecan-1 expression
To test whether the up-regulation of OPG after syndecan-1
knock-down in MCF-7 cells functionally affects osteoclast differ-
entiation, indirect co-culture experiments were performed. The
supernatants from control and MCF-7 cells treated with siRNA
against syndecan-1 were collected and transferred to osteoclasts.
After 21 days the number and activity of osteoclasts were
analyzed. Both parameters, osteoclast differentiation and activity,
were reduced by 21% and 23%, respectively (Fig. 5A and B).
The inhibition of osteoclastogenesis and activity was reversed by
addition of substances which neutralize OPG (OPG antibody/
RANKL).
4. Discussion
In this study, the expression and regulation of syndecan-1 in
breast cancer cells were investigated. Furthermore, we determined
the role of syndecan-1 in breast cancer pathophysiology and its
impact on tumor cell–osteoclast interaction.
Analyses of basal syndecan-1 expression showed differences in
syndecan-1 levels as well as staining pattern for this proteoglycan
in the breast cancer cell lines that were employed. Different
localization of syndecan-1 have been found in previous studies
showing lysosomal syndecan-1 in poorly differentiated cells, while
Fig. 3. Functional relevance of syndecan-1 (SDC1) modulation. Cells were serum starved 12 h prior to and during treatment. After DEX-treatment (106 M, 72 h) the
(A) viability of MCF-7 cells was analyzed. Additionally we investigated (B) apoptosis and (C) migration of DEX-treated MCF-7 cells. (D) Cell viability was assessed after SDC1
knock-down in MCF-7, T-47D and MDA-MB-231 cells. N¼3, npo0.05, nnpo0.01, DEX—dexamethasone, MDA-MDA-MB-231, RU—RU-486, SDC1 kd—syndecan-1 knock-down,
and scr. C—scrambled control.
Fig. 4. OPG is up-regulated after SDC1 knock-down in MCF-7 cells. After SDC1
knock-down cells were cultured in medium without FCS for 36 h. OPG expression
was analyzed using (A) real-time PCR and (B) ELISA. N¼4, npo0.05, nnnpo0.001,
SDC1 kd—syndecan-1 knock-down, and scr. C—scrambled control.
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a membranous pattern was present in more differentiated cell
lines [17,18]. This may also be the case in our study.
Despite numerous studies addressing the role of syndecan-1 in
breast cancer its function in this tumor entity remains incompletely
understood and only few regulators of syndecan-1 are known [1,3,
5–7,15,19–22]. In this study, we identiﬁed dexamethasone as an
inducer of membranous syndecan-1 expression in the MCF-7 cell
line. The other tested substances zoledronic acid and the aromatase
inhibitor did not alter syndecan-1 in any of the breast cancer cell
lines investigated. Interestingly, a recently published study reported a
signiﬁcant down-regulation of syndecan-1 in MCF-7 as well as MDA-
MB-231 cells by zoledronic acid when used at a concentration of
20 mM [12]. The use of a lower concentration of zoledronic acid in our
study could be a reason for this discrepancy.
Because of high levels of basal syndecan-1 expression and the
dexamethasone-mediated syndecan-1 up-regulation in MCF-7 cells,
further experiments were focused on this cell line. Next experiments
addressed the functional relevance of dexamethasone-mediated syn-
decan-1 up-regulation in MCF-7 cells. Since membrane-bound synde-
can-1 was reported to support proliferation and inhibit invasion of
breast cancer cells [5], we analyzed the cell viability and migration in
MCF-7 cells after dexamethasone treatment. We found a decrease
in cell viability after dexamethasone treatment whereas migration
was not altered. Because of this unexpected result we performed
syndecan-1 knock-down experiments in all three cell lines and
subsequently measured viability. Only the hormone receptor-positive
cell lines MCF-7 and T-47D responded with a decrease in cell viability
after syndecan-1 knock-down, but not the triple-negative MDA-MB-
231 cells. Thus, a certain threshold of syndecan-1 may be necessary for
the viability of hormone-responsive breast cancer cells but increased
levels do not further stimulate cell viability.
The fact that only the hormone receptor-positive cell lines
responded to the syndecan-1 knock-down raised the question
whether there is a link between the progesterone receptor status
and syndecan-1 expression. However, the data from the tissue
microarray did not support this assumption, as no correlation
between the syndecan-1 expression and progesterone receptor
status was found. This result is in line with two previous studies
showing no correlation between syndecan-1 and the progesterone
receptor status [9,10]. Nevertheless, another study found that a
high syndecan-1 expression correlated with a negative progester-
one receptor status [8]. In two of these three studies lobular and
other types of carcinomas were also included besides ductal
carcinomas, which may be the reason for these conﬂicting results
[8,9]. However, studies with a greater sample size are needed to
resolve this discrepancy.
The direct impact of soluble syndecan-1 on the bone compart-
ment was previously shown in two studies [14,15]. In a mouse
model of breast cancer, where heparanase-overexpressing MDA-
Met cells were used, osteoclastogenesis was enhanced and shown
to be dependent on the presence of syndecan-1 expression [15]. In
another study using a mouse model, syndecan-1-expressing multi-
ple myeloma cells produced fewer osteolytic lesions compared to
cells that did not express syndecan-1. Additional in vitro experi-
ments in murine bone marrow cells showed that the syndecan-1
ectodomain inhibits osteoclast formation and promotes osteoblast
development [14]. An indirect effect of syndecan-1 was also
discussed for multiple myeloma where the protein interaction with
OPG was proposed as a cause for lower OPG levels in patient with
osteolytic lesions compared to patients without this complication
[13]. In this study, we found that OPG expression was up-regulated
after syndecan-1 knock-down in MCF-7 cells. Thus, showing that
syndecan-1 does not only alter OPG function at the protein level,
but also at transcriptional level. Moreover, the modulation of OPG
by syndecan-1 knock-down was sufﬁcient to alter osteoclast biol-
ogy. Thus, our study supports the osteoclast-promoting effects of
syndecan-1 and identiﬁed it as a novel direct regulator of OPG.
5. Conclusion
In summary, we identiﬁed dexamethasone as an inducer of
syndecan-1 expression in breast cancer cells and show that
syndecan-1 represents a novel regulator of OPG expression. This
modulation of OPG inhibits osteoclastogenesis, which may be a
critical mechanism in the tumor cell/bone cell dialog.
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Fig. 5. Activity and genesis of osteoclasts is inhibited by indirect coculture with SDC1 insufﬁcient MCF-7 supernatant. Osteoclasts were cultured in medium containing
osteoclast culture media (one third) and supernatant of MCF-7 cells with and without SDC1 siRNA treatment (two thirds). Subsequently, the (A) number and (B) activity of
osteoclasts were assessed. N¼4, npo0.05, nnpo0.01, ab—antibody, and SDC1 kd—syndecan-1 knock-down.
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